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Abstract
We resequenced and phased 27 kb of DNA within 580 kb of the MHC class II region in 158 population chromosomes, most
of which were conserved extended haplotypes (CEHs) of European descent or contained their centromeric fragments. We
determined the single nucleotide polymorphism and deletion-insertion polymorphism alleles of the dominant sequences
from HLA-DQA2 to DAXX for these CEHs. Nine of 13 CEHs remained sufficiently intact to possess a dominant sequence
extending at least to DAXX, 230 kb centromeric to HLA-DPB1. We identified the regions centromeric to HLA-DQB1 within
which single instances of eight ‘‘common’’ European MHC haplotypes previously sequenced by the MHC Haplotype Project
(MHP) were representative of those dominant CEH sequences. Only two MHP haplotypes had a dominant CEH sequence
throughout the centromeric and extended class II region and one MHP haplotype did not represent a known European CEH
anywhere in the region. We identified the centromeric recombination transition points of other MHP sequences from CEH
representation to non-representation. Several CEH pairs or groups shared sequence identity in small blocks but had
significantly different (although still conserved for each separate CEH) sequences in surrounding regions. These patterns
partly explain strong calculated linkage disequilibrium over only short (tens to hundreds of kilobases) distances in the
context of a finite number of observed megabase-length CEHs comprising half a population’s haplotypes. Our results
provide a clearer picture of European CEH class II allelic structure and population haplotype architecture, improved regional
CEH markers, and raise questions concerning regional recombination hotspots.
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Introduction
The human major histocompatibility complex (MHC) is a
highly polymorphic genomic region of over 3 Mb on chromosome
6p21. MHC polymorphisms include critical determinants for
tissue transplantation success and show strong correlation both
with many genetic diseases and with ethnic origin. Haplotype
analysis of DNA sequence containing specific allele combinations
of two or more nearby genetic loci was first established in the
MHC. Many individuals within a human population share a small
number of specific MHC haplotypes. These 1 to 3 Mb stretches of
nearly identical MHC DNA sequence with high population
frequency are called conserved extended haplotypes (CEHs) [1–4]
or ancestral haplotypes [5,6]. Virtually all MHC allele-disease
associations involve marker alleles of CEHs [2–6].
Early work defined CEHs by their alleles at HLA-B, HLA-DR
loci and at intermediate MHC genes (i.e., ‘complotypes’ [7]). Later
CEH reports extended the core region from HLA-C to HLA-
DQB1. With technological refinements, it became clear individual
CEHs carry only one allele (or, rarely, a limited number of
variants) at any given locus in this region [2–6;8–16] without
apparent recombination. Intervening DNA sequence is therefore
essentially conserved (i.e., identical) among the population
haplotypes comprising each CEH, and CEHs are essentially
identical by descent common population haplotypes. CEH
sequence conservation has been verified whenever investigated,
whether determined by microsatellite, restriction fragment length
polymorphism, dense single nucleotide polymorphism (SNP) or
partial resequencing analyses of multiple haplotypes from unre-
lated individuals [9–13,15]. We have previously referred to the
existence of such ‘‘fixed’’ CEH alleles [1–4,8,14] and the
intervening sequence conservation of CEHs as ‘‘genetic fixity’’
[3,4,8,14–16].
We define genetic, haplotype or sequence ‘‘fixity’’ to be
sequence identity and conservation of a large stretch of genomic
sequence, shared by a relatively large number of apparently
PLOS Genetics | www.plosgenetics.org 1 October 2014 | Volume 10 | Issue 10 | e1004637unrelated individuals, without apparent recombination from an
ancestral sequence. By ‘‘identity’’ we mean ‘‘essential identity,’’
thus allowing for minor private mutation or microvariation within
individual haplotype sequences comprising a particular CEH (or
CEH fragment or block). Several studies have described the
extension of genetic fixity in some CEHs telomerically in the class I
region to HLA-A and centromerically in the class II region to
HLA-DPB1 [1–6,8,14–16]. However, little is known about CEH
alleles and conserved dominant sequences between HLA-DQB1
and HLA-DPB1 or those centromeric to HLA-DPB1. We sought
both to confirm the existence of sequence conservation in multiple
examples of a wide variety of CEHs and to identify the dominant
sequences centromeric to HLA-DQB1 for the core MHC CEHs
most similar to the previously sequenced ‘‘common’’ European
haplotypes [17–20].
Using consanguineous cell lines, the Wellcome Trust Sanger
Institute (http://www.sanger.ac.uk) undertook the MHC Haplo-
type Project (MHP) [17–20] (http://www.ucl.ac.uk/cancer/
medical-genomics/mhc) in which eight ‘‘common’’ European
MHC haplotypes were fully or nearly fully sequenced over a
genomic distance of up to 4.75 Mb. However, no systematic
analysis has determined whether these sequences accurately
represent the previously established CEHs [1–6]. As we argued
earlier [4], the extent to which the MHP sequences could be
exploited for deciphering genotype-phenotype relationships would
require resequencing multiple independent population haplotypes
to determine consensus sequence, microvariation, and population
representation for each CEH.
Here, we sought to answer two main questions: 1. Are the
centromeric portions of the MHP sequences representative of
European CEHs? 2. What is the extent of and sequence of a
retained dominant sequence centromeric to HLA-DQB1 for each
CEH ‘‘represented’’ by a MHP sequence? We compare the
classical HLA markers of the eight MHP sequences with the
analogous markers of previously reported European CEHs
[3,4,6,21]. Then, we describe partial resequencing of the region
centromeric to HLA-DQB1 of multiple population haplotypes for
each CEH these eight sequences putatively represent. The MHC
class II region centromeric to HLA-DQB1 is important both
because of its strong association with many complex diseases and
its known or suspected recombination hotspots [22,23]. We
document the extent of CEH dominant sequence conservation
from HLA-DQA2 to DAXX, and we identify the SNP and
deletion-insertion polymorphism (DIP) alleles of the dominant
sequence for each CEH. Finally, we identify where MHP
sequences accurately represent those dominant sequences, and
we discuss several structural and conceptual issues related to local
recombination hotspots and linkage disequilibrium (LD).
Results
MHP haplotypes: Some are CEHs and some are not
Five MHP haplotypes contain the markers of a previously
reported CEH [3,4,6,21] from HLA-C to HLA-DQB1 (what we
define as the ‘‘core’’ or ‘‘classical’’ (for CEH purposes) MHC
region). HLA specificities are used in Table 1 to designate each
CEH name for historical reasons. The five apparent MHP CEHs
are: PGF, the human reference sequence for the MHC, containing
the core MHC markers of the CEH ‘‘B7,DR15’’; COX,
representing the CEH ‘‘B8,DR3’’; QBL, representing the CEH
‘‘B18,DR3’’; MANN, with the core MHC markers of two
‘‘B44,DR7’’ CEHs (exhibiting both HLA-C*04/C*16 variation
and, independently, C4A*0/C4A*3 microvariation); and, DBB,
representing the CEH ‘‘B57,DR7.’’
The other three MHP cell lines do not contain a previously
described MHC CEH, and it is therefore uncertain how
‘‘common’’ these haplotypes are in any European population.
SSTO contains HLA-DQB1*03:05, a DQ8 specificity allele, but
is not a reported CEH. Several reported CEHs contain a
DR4,DQ8 specificity block (like SSTO) MHC haplotype,
although they all have HLA-DQB1*03:02 alleles. The MCF
haplotype exists in our database only once and is not a known
CEH [21]. The CEH ‘‘B44,DR4,DQ7’’ (in which there is
C4B*Q0/C4B*1 microvariation) is the reported CEH most
similar to MCF in the class II region. (HLA-DQB1*03:01 is a
DQ7 specificity allele.) Finally, the APD MHC haplotype (HLA-
C*06:02, B*40:01, DRB1*13:01, DQB1*06:03) does not exist
among our 2675 normal Boston haplotypes [21] and has not been
reported to be a CEH. In the core MHC region, the CEH [HLA-
C*03:04, B*40:01, SC02, DRB1*13:02, DQB1*06:04]
(‘‘B60,DR13’’) is the reported CEH [3,4,6,21] most similar to
the APD haplotype. (HLA-B60 is the specificity of the HLA-
B*40:01 allele in this CEH.)
Haplotype resequencing strategy
After aligning MHP sequences [18–20], we chose centromeric
class II amplicons that would maximize the resultant SNP-DIP
haplotypic variation if the MHP sequences were representative of
common population haplotypes. We supplemented our initial
choices with amplicons to localize transition points where MHP
sequences ceased to represent common long-range haplotypes. We
designed 56 primer pairs to sequence amplicons in five regions
from HLA-DQA2 to DAXX (Figure 1). We resequenced about
27 kb of this 580 kb region. HLA-DQA2 and DAXX are located
approximately 80 kb and 660 kb centromeric to HLA-DQB1,
respectively. The sequenced amplicons and their polymorphisms
we report along with their human genome (assembly 37.p10)
locations and rs number designations are given in Table S1 and
Table S2. Where known polymorphisms are missing in Table S2
from genomic locations within the boundaries of amplicons
Author Summary
The human major histocompatibility complex (MHC) is a
gene-dense region highly enriched in immune response
genes. MHC genetic variation is among the highest in the
human genome and is associated with both tissue
transplant compatibility and many genetic disorders.
Long-range (1–3 Mb) MHC haplotypes of essentially
identical DNA sequence at relatively high ($0.5%) popu-
lation frequency (‘‘genetic fixity’’), called conserved ex-
tended haplotypes (CEHs), comprise roughly half of all
European population haplotypes. We sequenced an
aggregate of 27 kb over 580 kb in the MHC class II region
from HLA-DQA2 to DAXX in 158 European haplotypes to
quantify the breakdown of this genetic fixity in the
centromeric portion of the MHC and to determine the
representative nature within that region of eight previ-
ously fully or nearly fully sequenced ‘‘common’’ European
haplotypes. We identified the dominant sequences of 13
European CEHs and determined where the ‘‘common’’
sequences did (or did not) represent related CEHs. We
found patterns of shared sequence identity among
different CEHs surrounded by fixed (for each CEH) but
differing sequence. Our direct observational results for
population haplotypes explain the mutual occurrence of
CEHs and short (5–200 kb) blocks of fixed sequence
detected by the statistical measure of linkage disequilib-
rium.
CEH Dominant Sequences from HLA-DQA2 to DAXX
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matched the human reference sequence.
We determined the phased sequences of 158 population
haplotypes primarily through segre g a t i o na n a l y s i si np e d i g r e e s .
For each pedigree, we determined between two and four
founder haplotypes, varying by the number of unrelated
haplotypes identifiable in the subjects available for each
pedigree. All haplotypes followed Mendelian inheritance pat-
terns except for rare null alleles and intra-family crossovers. For
the latter, as with all pedigrees, we only report the unrelated
non-crossover founder haplotypes. We achieved 91% to 100%
sequence completion in the amplicons from HLA-DQA2
through HLA-DMA and from RING1 through DAXX, 85%
sequence completion fort h e1 5 8h a p l o t y p e si nBRD2 and about
45% to 65% completion from HLA-DOA through HLA-DPB1.
Text S1 provides details about the population haplotypes chosen
for each CEH group, and Table S3 provides details of the
resequencing coverage (i.e., completion) for each haplotype
group and region. Table S5 provides the complete phased SNP-
DIP sequence data for all 158 haplotypes and the eight MHP
haplotypes for a central portion of the covered region from
HLA-DOB to BRD2.T a b l eS 4p r o v i d e st h eM H Pa n d
dominant CEH sequences from HLA-DQA2 to DAXX,i n c l u d -
ing the annotated genomic locations of the SNPs and DIPs. The
dominant sequences were taken from Table S5 and analogous
data from other regions. The CEH groups are organized in
numerical order by their HLA-DR/DQ specificities.
MHP cell line sequence results for regions not previously
reported
Some current MHC haplotype scaffolds contain sequence gaps
for and/or do not extend centromerically to several of the
amplicons we sequenced. We sequenced the QBL (Figure S1),
MANN (Figure S2) and DBB (Figure S3) haplotypes within those
amplicons. The SNP and DIP alleles within those amplicons for
the three MHP haplotypes are highlighted both within the
sequences shown in Figures S1–S3 and surrounded by yellow
borders in the summary Table S4 and in Table S5. These
sequences have assigned GenBank accession numbers as described
in the Materials and Methods and the Figures.
New QBL sequences. At amplicon DOB1, only 529
nucleotides of this 549 bp region were clearly sequencable due
to the homopolymeric region toward the centromeric end, which
made the 39 end of the forward strand unreadable (Figure S1). The
529 nucleotide region of QBL was identical in length to the
comparable region of the human reference sequence (PGF), but
QBL and PGF differed by one nucleotide at each of the two DIPs
(Table S4 and Table S5). However, the two sequences were
identical at every SNP. For the other amplicons, all nucleotides
between the primers were sequenced. QBL was identical to the
human reference sequence in amplicon DOB4. In amplicon
DOB5, the QBL sequence differed at the third SNP, but the
sequences were otherwise identical.
New MANN sequences. At amplicons DOB4 and DOB5,
within and 2 kb centromeric to HLA-DOB, respectively, MANN
(Figure S2) was identical to the QBL sequence, as it was for most
of the telomeric region we resequenced. MANN was still
representative of its two CEHs within these two amplicons (please
see below).
New DBB sequences. At amplicon DMP7, only 546
nucleotides of this 599 bp region were clearly sequencable in
DBB (Figure S3) due to a homopolymeric region toward the
centromeric end, which made the 39 ends of both strands
unreadable. Only 53 of these 546 nucleotides overlapped between
the forward and the reverse sequences in DBB. However, of the
546 bp sequenced on either (or both) strand(s), only the fourth
SNP differentiated this sequence from the human reference
sequence and most other haplotypes (Table S4 and Table S5). For
the other two regions, DMP8 and DMP9, all nucleotides between
the primers were sequenced, and the forward and reverse readable
sequences largely overlapped. At amplicon DMP8, DBB was
identical in length to the human reference sequence but differed at
the penultimate SNP. In the DMP9 region, the DBB sequence was
identical both in length and sequence to the human reference
sequence.
MHP sequence representation of population haplotypes
in the class II region
We compared the sequences of the five MHP haplotypes (PGF,
COX, QBL, MANN and DBB) containing markers of specific
CEHs in the core MHC with population haplotypes bearing the
same CEH markers (Table 1). We also compared both the PGF
and MANN haplotypes each with a second CEH with which they
shared HLA-DRB1 and HLA-DQB1 alleles. We compared SSTO
Figure 1. A map of the MHC class II and extended class II regions of chromosome 6p21. Sequenced sub-regions are marked by colored
blocks (top). Distances (kb) are to scale from the human reference sequence. Gene locations from HLA-DRA on the telomeric (T) end to DAXX on the
centromeric (C) end are shown.
doi:10.1371/journal.pgen.1004637.g001
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allele or sequence identity. Because 90% of the 50 DR4,DQ8
haplotypes we sequenced shared identity to SSTO in the HLA-
DQA2 and HLA-DQB2 regions, we compared SSTO with the
sequences of all six resequenced DR4,DQ8 CEHs (Table 1). We
compared the MCF sequence with the only known CEH with
which it shares HLA-DR/DQ alleles (please see above). Finally,
we compared the APD sequence with the only DR13 population
haplotype (out of 13 total) we sequenced having an identical HLA-
DQA2 to HLA-DOB sequence. We therefore did not compare the
APD sequence with any known CEH because no known CEH
shared sequence identity with APD.
The break point (or lack thereof) at which a MHP sequence no
longer represented any CEH is shown in Figure 2. The APD cell
line is not shown in Figure 2 because it does not represent a
reported CEH. Figure 2 displays were based on analyses of
sequences shown in Table S4, and those analyses were based on
phased data (Table S5 and analogous data in other regions). PGF
had the B7,DR15 CEH dominant sequence and QBL had the
B18,DR3 CEH dominant sequence throughout the HLA-DQA2
to DAXX region (Figure 2). PGF also represented the B18,DR15
CEH up to a point within the 1 kb region from intron 8 to intron 6
of TAP2 (Table S4 and Table S5), where this CEH’s dominant
sequence began to differ from that of the B7,DR15 CEH.
The other five MHP sequences represented at least one CEH in
class II for variable distances. We determined precisely the
centromeric break point for the COX sequence. Twenty-five of
the 30 B8,DR3-like haplotypes showed sequence identity to COX
from HLA-DQA2 through the DOB9 amplicon within intron 6 of
TAP2. However, within the same intron, at rs60045856 (SNP ID
#147, Table S2), less than 600 bp centromeric to the DOB9
amplicon, the COX sequence differed from all of the previously
identical 25 haplotypes (Table S4 and Table S5). The G allele at
rs60045856 appeared to be a regional tag marker of the B8,DR3
CEH in that all 25 haplotypes identical to the COX sequence up
to the DOB9 amplicon possessed this allele whereas all of the other
133 haplotypes reported here (as well as COX and the other seven
MHP sequences) had the T allele (Table S5). COX never shared
significant regional sequence with the dominant B8,DR3 sequence
centromeric to TAP2.
MANN represented two related B44,DR7 CEHs through at
least a region 2 kb centromeric to HLA-DOB (amplicon DOB5).
Approximately 5.5 kb telomeric to TAP2, where the two
B44,DR7 CEH dominant sequences diverged, MANN continued
to represent the C4,B44,DR7 CEH (despite MANN carrying the
HLA-C*16:01-defining allele of the C16,B44,DR7 CEH). Within
intron 8 of TAP2, the C4,B44,DR7 dominant sequence split into
major and minor variants, and MANN ceased to represent either
B44,DR7 CEH dominant sequence, although it continued to be
identical to the B49,DR4,DQ8 CEH throughout all of the TAP2
amplicons we sequenced (Table S4 and Table S5). DBB possibly
represented the B57,DR7 CEH throughout the class II region in
which the CEH maintained a dominant sequence. We could not
pinpoint the end of representation by DBB or MCF due to
incomplete sequencing (Figure 2; Text S1). However, MCF
stopped representing its CEH within the 26.9 kb region at or
centromeric to BRD2 (Table S4), telomeric to lost CEH fixity.
Of the seven MHP sequences in Figure 2, SSTO represented its
nearest CEH group for the shortest distance. The centromeric
break point for SSTO representation of the CEH HLA-
B62,SC33,DR4,DQ8 was within a 13.5 kb region between
HLA-DQB2 and HLA-DOB. The SSTO centromeric break point
for any DR4,DQ8 CEH was narrowed to a different 11.2 kb
region between HLA-DQB2 and HLA-DOB (Table S4). However,
we can predict the latter break point more precisely using MHP
sequence data. Telomeric to rs9276712 (SNP ID #89, amplicon
DC13, Table S2), SSTO was identical to the CEHs HLA-
B62,SB42,DR4,DQ8, HLA-B60,SC31,DR4,DQ8 and HLA-
B38,SC21,DR4,DQ8 and was highly similar to the PGF sequence
but differed significantly from the APD sequence. At and
centromeric to rs9276712 (for 141 kb, until amplicon DMP1),
the SSTO sequence was highly similar to APD but significantly
different from PGF (which remained highly similar to the three
CEHs). The recombination event that caused this SSTO switch
from similarity to PGF to similarity to APD was likely between
rs9276712 and rs1158783, the last SNP telomeric to rs9276712 at
which the telomeric APD-PGF-SSTO pattern was clear. The
distance between the two SNPs is 286 bp in the human reference
sequence.
Only one private mutation was found in a MHP sequence
In an attempt to identify SNP/DIP markers near TAP2
differentiating the relatively similar sequences of the B18,DR3
CEH (represented by QBL) and the B44,DR7 CEHs (represented
by MANN), we resequenced B44,DR7 haplotypes (including
MANN) at the DOB7.5 amplicon (Table 2). Among the eight
MHP sequences, only MANN had a T allele at SNP DOB7.5-2
(rs2857100; ID #2, Table 2). We confirmed this by sequencing
Figure 2. MHP sequences represent CEHs to variable extents in
MHC class II from HLA-DQA2 to DAXX. MHP cell line names (left) and
their complotypes (when known) and some of their HLA alleles are
above their corresponding lines. Shown is the region (solid horizontal
line) in which the listed MHP sequence represented the dominant CEH
sequence sharing MHC markers identical or similar to the cell line. Cell
line specificities or alleles sometimes differed from the ‘‘represented’’
CEHs (see text). A dashed line indicates the region within which a break
point between the shared identity of the MHP sequence and the
dominant sequence occurred but could not be precisely localized. Icons
at the ends of MANN, COX and SSTO show precise break points of
shared sequence identity. The relative location of several class II genes
(telomere toward centromere from left to right) is shown to scale on the
abscissa.
doi:10.1371/journal.pgen.1004637.g002
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B44,DR7 haplotypes we sequenced (including all five essentially
identical to MANN telomeric to the DOB7.5 amplicon) had the C
allele at rs2857100. We concluded the MANN haplotype had a
private mutation at rs2857100. If the T allele exists in other
B44,DR7 haplotypes, the frequency is likely to be extremely low.
This was the only private SNP allele we found in any MHP
sequence within a region in which it otherwise had the dominant
sequence of a CEH it represented.
Dominant sequences of CEHs and their loss of sequence
conservation due to recombination in the class II region
From HLA-DQA2 to HLA-DQB2, all CEHs retained a
dominant sequence (i.e., maintained ‘‘genetic fixity’’) shared by
50 to 100% of the population haplotypes in each group
(Figure 3A-C). Most CEHs also retained a dominant sequence
by DAXX (660 kb centromeric to HLA-DQB1), although there
was usually a gradual reduction in the number of population
haplotypes sharing that sequence. CEH dominant sequence results
are organized based on the MHP cell line sequences in the order
in which they were published. Complete detail of fixity loss for
each CEH is provided in Text S1. No results are presented for the
DR13,DQ6 CEH because APD did not represent that CEH in the
regions we resequenced.
Loss of sequence fixity (Figure 3A–C) is in terms of the gene
and/or amplicon at which individual haplotypes stopped sharing
SNP/DIP alleles of their CEH dominant sequence. Minor
variations, almost always apparently unlinked and isolated private
SNPs or DIPs and isolated dominant sequence microvariation,
were not counted as loss of sequence fixity (e.g., Table S5). CEH
fixity loss is therefore due to past recombination of the dominant
sequence with other haplotype sequences. This conclusion is
strengthened by our observation that sequences centromeric to the
dominant sequence break point are rarely unique and are often
found in other CEH groups (e.g., Table S5). We therefore make
the explicit assumption that intervening unsequenced regions of
population haplotypes sharing a CEH dominant sequence (i.e.,
telomeric to the break point for any given population haplotype)
have similarly limited microvariation and are essentially identical
sequences.
Although recombination is the explanation for population
haplotype crossover from a CEH dominant sequence (previously
identical by descent), it is not possible to calculate CEH
recombination rates. The number of meioses experienced by the
CEH prior to (or since) its recombination to form any particular
population haplotype is unknown. To quantify and display
observed population haplotype recombinants responsible for the
breakdown of each CEH dominant sequence, we developed a new
metric, normalized crossover frequency (NCF, see Materials and
Methods ). Our sequencing amplicons and data were not
distributed evenly across the region analyzed (Figure 1, Table
S1, Table S2, Table S4). We therefore display NCF values,
calculated for 11 separate sub-regions (see Materials and Methods
and Table S2), on genomic maps drawn to scale (Figure 3D–O).
The areas and locations of the bars in those figures quantify and
localize the effect of recombination on the loss of CEH fixity
displayed in Figure 3A–C.
Sequence recombination is difficult to localize with precision
(please see below). Furthermore, the breakdown of a CEH
dominant sequence likely varies in different population
cohorts. Nevertheless, a few general observations are evident
from the results shown in Figure 3. First, the breakdown
locations and frequencies vary significantly between different
CEHs. Although certain sub-regional crossover sites are more
common (e.g., between HLA-DQB1 and HLA-DQA2 (sub-
region 1), between HLA-DQB2 and HLA-DOB (sub-region 3),
between TAP2 and HLA-DMA (sub-region 6), between BRD2
and HLA-DPB1 (sub-regions 8 and 9), and between HLA-
DPB1 and VPS52 (sub-region 10)), none is common to the
majority of all analyzed CEHs. Also, some dominant sequences
break down gradually in many locations whereas others seem
to break down in a more focused fashion. These differences
may be due to different relative timelines of CEH expansion
and recombination events. Finally, while specific CEHs show a
range from high to no sequence conservation through DAXX,
most CEHs show approximately 50% dominant sequence
retention around BRD2 (in sub-region 7, between HLA-DMB
and HLA-DOA). Below, we highlight the results for specific
CEHs.
Sequence fixity of HLA-DRB1*15:01,-DQB1*06:02 CEHs
The precise location (and, consequently, quantitation) of
historic recombination leading to the breakdown of a dominant
sequence is often not definable. Perhaps the clearest example of
this is the apparent strong crossover frequency for the B7,DR15
CEH in TAP2 (sub-region 5, Figure 3D). Sequence fixity was
maintained for 19 of 23 (83%) B7,DR15 haplotypes from HLA-
DQA2 through intron 8 of TAP2 (Figure 3A). Beginning in
intron 6 of TAP2, fixity of the B7,DR15 CEH declined to 14
haplotypes (61%), and was maintained through TAP2.T h e
detected crossover of five B7,DR15 haplotypes was to a
sequence that defined the B18,DR15 CEH dominant sequence.
Thus, the crossovers detected within TAP2 in these five
haplotypes could have occurred anywhere within the region
shared by the two CEHs. That region extends telomerically past
HLA-DRB1. The B18,DR15 CEH dominant sequence from
HLA-DQA2 to BRD2 (apparently identical to the B7,DR15
dominant sequence through intron 8 of TAP2)w a sf o u n di n
80% of the population haplotypes we resequenced (Table S4
and Table S5).
B7,DR15 haplotype resequencing centromeric to TAP2 showed
a gradual loss in CEH fixity through DAXX (Figure 3A) and
declined below 50% near HLA-DMB. The nine B7,DR15
haplotypes identical at HLA-DPB1 (39% of the original 23)
either had the unique exon 2 sequence of or were classically typed
as HLA-DPB1*04:01. The dominant B7,DR15 CEH sequence
from HLA-DQA2 through DAXX was found in 26% of all
resequenced B7,DR15 haplotypes.
Table 2. Amplicon DOB7.5 SNPs determined from resequencing.
Amplicon ID Gene/Region rs# Location
DOB7.5-1 TAP2 2857101 32,794,676
DOB7.5-2 TAP2 2857100 32,794,856
doi:10.1371/journal.pgen.1004637.t002
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and starts at the mid-point between HLA-DRB1 and HLA-DQB1 (A–C) or at HLA-DQB1 (D–O). The locations of several HLA class II and extended class II
genes are marked by arrows below Figures 3A–C and 3O. The 11 regions analyzed for normalized crossover frequency (NCF) are enumerated in
Figure 3D. The numbers of haplotypes analyzed for each CEH are given in Table 1. Sequence fixities (A) and NCFs (D–F) are shown for the CEHs
B7,DR15 (black open circles), (D); B8,DR3 (green closed circles), (E); and B18,DR3 (red squares), (F). Sequence fixities (B) and NCFs (G–J) are shown for
the CEHs C4,B44,DR7 (green closed circles), (G); C16,B44,DR7 (purple open circles), (H); B57,DR7 (red squares), (I); and B44,DR4,DQ7 (blue diamonds),
(J). Asterisks (*) in Figures 3B, 3G and 3H indicate that sequence fixities and NCFs could not be determined centromeric to the last data points for the
two B44,DR7 CEHs. Sequence fixities (C) and NCFs (K–O) for various DR4,DQ8 CEHs are shown. These include the CEHs B44,SC30/SC31 (black
diamonds), (K); B62,SC33 (green closed circles), (L); B38,SC21 (purple open circles), (M); B60,SC31 (red squares), (N); and B62,SB42 (blue triangles), (O).
NCFs are normalized to the remaining conserved sequences and to 1 Mb relative to the distance over which crossovers were observed, and values
are displayed for 11 sub-regions (Table S2).
doi:10.1371/journal.pgen.1004637.g003
CEH Dominant Sequences from HLA-DQA2 to DAXX
PLOS Genetics | www.plosgenetics.org 7 October 2014 | Volume 10 | Issue 10 | e1004637B8,DR3 CEH sequence fixity
All 30 B8,DR3 haplotypes were identical at HLA-DQA2.
Sequence conservation decreased to 29 haplotypes (97%) at HLA-
DQB2, to 87% at 16.4 kb centromeric to HLA-DQB2 (amplicon
DC10) and to 25 haplotypes (83%) from HLA-DOB through
TAP2 (Figure 3A). B8,DR3 sequence fixity decreased below 50%
in the 20 kb region between amplicons DMP10 and DMP11 and
declined to 40% at HLA-DOA (sub-region 8, Figure 3E). Seven of
the 30 haplotypes (23%) had the dominant sequence and were
essentially identical through DAXX. Six of those contained HLA-
DPB1*01:01 (the seventh had HLA-DPB1*03:01). (If the
haplotype with HLA-DPB1*03:01 is different from the other
six (in spite of having essentially identical SNP-DIP alleles from
HLA-DQA2 to DAXX), the dominant sequence at DAXX would
be represented by only six of 30 (20%) of the studied haplotypes
rather than 23%.)
B18,DR3 CEH sequence fixity
Only 12 of the 18 (67%) B18,DR3 haplotypes showed sequence
identity at HLA-DQA2 (Figure 3A). In contrast to this relatively high
crossover frequency between HLA-DQB1 and HLA-DQA2 (sub-
region 1; Figure 3F), 61% of all 18 haplotypes remained essentially
identical to one another and QBL from HLA-DQB2 through BRD2.
The only microvariation found among these 11 haplotypes was at the
second BRD2 DIP (ID #204; Table S2). By DAXX,n i n eo ft h e1 8
(50%) sequences were still essentially identical.
Sequence fixity of B44,DR7 CEHs
All 10 B44,DR7 haplotypes shared sequence identity from
HLA-DQA2 through 21 kb telomeric to HLA-DOB (amplicon
DC13), and 90% of the haplotypes remained essentially identical
up to 6.5 kb centromeric to HLA-DOB (Figure 3B). As outlined in
Text S1, we studied six C4,B44,DR7 (Figure 3G) and four
C16,B44,DR7 (Figure 3H) haplotypes. The dominant sequences
of these two CEHs became different near and within TAP2 (Table
S4 and Table S5). The DOB6 DIP at 5.5 kb telomeric to TAP2
and the DOB7-2 SNP 2.8 kb telomeric to TAP2 defined this split.
The four C16,B44,DR7 examples we sequenced maintained
sequence identity to one another for the remaining amplicons in
TAP2 and three of these (75%) remained identical through the
BRD2 region. The five essentially identical C4,B44,DR7 haplo-
types split into two groups within intron 8 of TAP2 (at SNP
DOB8.4). The dominant sequence, in three of the haplotypes
(50%) appeared to be shared through at least 2 kb telomeric to
BRD2. We did not sequence the haplotypes comprising the
dominant sequence of either CEH sufficiently to determine the
extent (or lack) of sequence identity centromeric to BRD2.
B57,DR7 CEH sequence fixity
Three of the four (75%) B57,DR7-like haplotypes shared a
common sequence from HLA-DQA2 through approximately
16.5 kb centromeric to HLA-DQB2. Sequence fixity declined to
two of the four (50%) haplotypes between HLA-DQB2 and HLA-
DOB (Figure 3B; sub-region 3, Figure 3I) and continued through
BRD2. We did not sequence the two identical haplotypes from
HLA-DOA (amplicon DMP11) through HLA-DPB1 (amplicon
DMP17), but we began sequencing again just centromeric to
RING1 (at amplicon CTB8). At amplicon CTB8, those two
haplotypes remained identical to one another. However, 4.5 kb
centromeric, at amplicon CTB9, the two haplotypes also differed
from one another. Thus, we could only localize the B57,DR7
CEH lost fixity to a 244 kb region between amplicons DMP10 and
CTB9 (Figure 2 and Figure 3B).
B44,DR4,DQ7 CEH sequence fixity
Although there was a significant loss of CEH sequence fixity
between HLA-DQB1 and HLA-DQA2, four of the seven (57%)
B44,DR4,DQ7 haplotypes retained identical sequence from
within intron 1 of HLA-DQA2 through at least HLA-DOA
(Figure 3B and Figure 3J). Within the first intron of HLA-DPA1
(amplicon DMP15), the number of identical CEH sequences
decreased to three haplotypes (43%). The haplotype that became
different was not sequenced at amplicon DMP14. The three
identical haplotypes retained sequence identity to one another
through DAXX. The sequence presented in Table S4 contains
HLA-DPB1*04:01 and represents the dominant B44,DR4,DQ7
CEH sequence.
Sequence fixity of DR4,DQ8 CEHs
Class II fixity of DR4,DQ8 CEHs. Of the 50 sequenced
DR4,DQ8 haplotypes, 41 represented six CEHs (Table 1). Forty-
five of these were essentially identical to the SSTO sequence from
HLA-DQA2 through HLA-DQB2 (amplicon DC9; Table S4).
Four of five non-SSTO sequences had a different common
sequence from HLA-DQA2 to 16.4 kb centromeric to HLA-
DQB2 (amplicon DC10). Three of the four (75%) comprised half
the examples we sequenced of the B44,DR4,DQ8 CEH. The fifth
non-SSTO sequence was the sole example of the B49,DR4,DQ8
CEH.
The 45 DR4,DQ8 haplotypes identical at HLA-DQA2 and
HLA-DQB2 included 33 of the 34 (97%) haplotypes comprising
the other four CEHs. These CEHs shared identical sequence both
in that region and in a 45 kb region from HLA-DMB through
BRD2 (boxed region in Table S4). However, the dominant
sequences of these four major DR4,DQ8 CEHs differed from one
another within the intervening 170 kb.
B49,DR4,DQ8. This haplotype differed from all other
DR4,DQ8 haplotypes at and centromeric to HLA-DQA2 (Table
S4). Whether this single sequence represents the CEH is unknown
at this time.
B44,DR4,DQ8. Of six examples with the markers of this
CEH, two had the SC30 complotype and four had SC31. C4B
microvariation did not correlate with differences among the six
haplotypes at or centromeric to HLA-DQA2. The B44,DR4,DQ8
CEH had two equally representative centromeric class II
sequences and was the least fixed CEH (Figure 3). From HLA-
DQA2 to HLA-DOB, three of the six haplotypes (50%) remained
identical to one another (and most other DR4,DQ8 haplotypes).
Just 2 kb centromeric to HLA-DOB, one sequence became
different. Within intron 9 of TAP2 (at amplicon DOB9), the
remaining two haplotypes lost sequence identity to one another.
The other three B44,DR4,DQ8 haplotypes (50%) shared a
different sequence from HLA-DQA2 through amplicon DC10,
identical to DBB. At amplicon DC13 and centromeric through
ZBTB22, two of the three haplotypes had a unique common
sequence that differed from DBB. Thus, two of the original six
B44,DR4,DQ8 haplotypes (33%), both of which were typed as
HLA-DPB1*04:01, maintained a fixed and identical sequence
through ZBTB22, approximately 650 kb centromeric to HLA-
DQB1 (Figure 3C and Figure 3K, Table S4).
B62,SC33,DR4,DQ8. Sequence fixity for this CEH declined
steadily, and three (38%) retained the dominant sequence of this
CEH through DAXX (Figure 3C and Figure 3L).
B38,SC21,DR4,DQ8. This CEH had the highest fixity at
DAXX of all the CEHs we studied (Figure 3C and Figure 3M),
and eight haplotypes (88%) remained identical to one another
through DAXX.
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declined steadily (Figure 3C and Figure 3N). HLA-DPB1 typing
and centromeric sequence analysis suggested that fixity decreased
to 20% at that locus and continued centromeric to DAXX.
B62,SB42,DR4,DQ8. From HLA-DQA2, all seven examples
of this CEH retained a unique dominant sequence through BRD2.
From HLA-DOA to HLA-DPB1, the fixity of this CEH declined
steadily to 29% (Figure 3C and Figure 3O). One of those two
fixed haplotypes was typed as HLA-DPB1*04:01.
Sequence fixity of DR13,DQ6 haplotypes
Although APD did not represent any known CEH in the
resequenced region, APD shared sequence identity with its single
represented population haplotype from at least HLA-DQA2
through TAP2, a distance of almost 100 kb. The previously
identical sequence differed from the APD sequence at every SNP
2.1 kb telomeric to HLA-DMB but was otherwise identical at
amplicons DMP2 through DMP6. Within and near HLA-DMB
and HLA-DMA (amplicons DMP1-6), no other haplotype we
sequenced had the APD sequence, and only two other haplotypes
(both non-standard haplotypes from other groups) had the same
sequence as the DR13,DQ6 haplotype we report in Table S4. The
APD sequence in amplicons DMP7 through DMP13 has not been
reported, but its sequence near and in the HLA-DP genes differed
from the other DR13,DQ6 haplotype we report.
Discussion
Identifying the genetic elements responsible for complex genetic
diseases requires knowing the genomic haplotype architecture of
the population(s) in which the diseases exist. Toward that goal, the
MHP made a major advance in the early to mid-2000’s by
determining the sequences of eight European Caucasian MHC
haplotypes [17–20]. However, although the MHP sequences were
described as ‘‘common’’ European Caucasian MHC haplotypes,
that remains an open question [4]. Other than a comparison of the
eight sequences with 180 European Caucasian population
haplotypes at 54 SNPs covering 214 kb of the MHC class II
region (from HLA-DRB9 to 20 kb centromeric to HLA-DQB1
(Figure 1)) [20], no systematic study has determined the repre-
sentative nature of each MHP haplotype’s complete sequence.
MHC CEHs are common population haplotypes [1–6,8–16].
Outside of their core conserved region from HLA-C to HLA-
DQB1, CEHs contain dominant alleles on the telomeric class I
side at HLA-E [14] and HLA-A [1–6,8–11], which is consistent
with the region between HLA-A and HLA-C being one of notably
low recombination [22]. The class II region between HLA-DQB1
and DAXX is thought to be less conserved than that analogous
distal class I region, and class II contains several reported
recombination hotspots [22,23] and regional LD breaks [24]
(which are thought to be related). Furthermore, the best-
characterized CEH, [HLA-B8, SC01, DR3], previously showed
significant variability centromeric to HLA-DQB1 [9,10,25]. By
contrast, previous reports also documented dominant HLA-DPB1
alleles for a number of European Caucasian CEHs [3,4,15],
including the B8,DR3 (in shortened nomenclature) CEH.
We used an amplicon resequencing approach [10] to determine
the dominant class II sequences centromeric to HLA-DQB1 and
to delineate the breakdown of sequence conservation among
multiple examples of previously identified CEHs sharing telomeric
class II alleles or specificities with the eight MHP sequences. The
dominant class II sequences were unique for each CEH, and we
confirmed or discovered over 300 SNP and DIP markers. The
phased polymorphisms of each CEH dominant sequence are
shown in Table S4. Most CEHs showed significant sequence
conservation (‘‘fixity’’) centromeric to HLA-DQB1, crossing
multiple reported recombination hotspots [22,23]. Although a
few CEHs lost a dominant sequence by DAXX (660 kb
centromeric to HLA-DQB1), most CEHs retained a dominant
sequence throughout the region. Seven of the eight MHP
sequences represented the dominant class II sequence of at least
one CEH for varying distances.
Several general observations derive from our data. First,
microvariation was low within a CEH’s dominant class II
sequence, even at DIPs, similar to findings within the core
MHC for the two CEHs previously reported [9–11]. We detected
only a single private mutation among the MHP sequences within
regions where they otherwise represented the dominant sequences.
These findings suggest CEH sequences are recent enough not to
have sustained significant mutation during their expansion.
Second, CEH dominant sequence conservation appears to be lost
primarily due to recombination events with other relatively high
frequency haplotypes because non-consensus sequences centro-
meric to the point of differentiation typically are identical to other
common regional sequences. These are often the local fragments
of other CEH dominant sequences. Third, except in a few cases
where CEHs split apart from a common sequence shared by
related CEHs, the dominant sequences did not usually transition
to multiple examples of a conserved minor sequence past the
recombination point. Although this last observation remains to be
confirmed in studies of larger numbers of the same CEH, it also
suggests the minor variant recombinants are relatively recent
compared to the ages of the original CEHs.
A fourth conclusion is somewhat complex. Although the
location of dominant sequence breakdown varied between CEHs
(Figure 3D–O) and did not appear to be primarily at previously
reported recombination hotspots or LD breaks [22–24], many
CEHs showed a steady loss of fixity throughout the region. The
major reported recombination hotspots in the region are [22–24]:
a) between HLA-DQB1 and HLA-DQA2 (near MTCO3P1) [22];
b) within intron 2 of TAP2 (just centromeric to the most
centromeric amplicon of TAP2 we sequenced) [22]; c) just
telomeric to HLA-DMB, near the next amplicon we sequenced
centromeric to TAP2 [23]; d) between BRD2 and HLA-DOA
[22,23]; e) between HLA-DOA and HLA-DPA1 [22,24]; and, f)
between HLA-DPB1 and RING1 [24]. However, losses of
sequence conservation occurred in the region between HLA-
DQA2 and intron 2 of TAP2, a region not previously reported to
contain a recombination hotspot.
Our directly observed haplotype results reveal complexity
missed by a casual analysis of LD maps. The results we present
regarding CEH structure renew questions we previously raised
regarding both LD and recombination hotspots [3]. However, our
study was not designed to identify nor to challenge the existence of
recombination hotspots in the extended class II region, and further
study of this region is warranted.
An interesting feature of several CEH pairs and groups is a
pattern of shared sequence identity surrounded both telomerically
and centromerically by regions in which the CEHs differ
significantly (Figure 4). This ‘‘block’’ nature of CEHs and
haplotype groups sharing regional alleles has been noted
previously [3–8,13–16,19,22,25]. The MHP reported [19] a
158 kb ‘‘SNP desert’’ from HLA-DRB1 and MTCO3P1 between
the two DR3 CEHs (Figure 4A). Our study expands upon that
concept and provides a richer picture of these relationships.
For example, the B7,DR15 and B18,DR15 CEHs were
previously known to share alleles within the HLA-DR/DQ block
[1,3–6,8], but it was unknown whether they had identical or
CEH Dominant Sequences from HLA-DQA2 to DAXX
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these two CEHs share sequence identity throughout the 88 kb
stretch from HLA-DQA2 through intron 8 of TAP2, centromeric
to which they maintain fixed but distinctly different sequences
(Figure 4B). Although the two CEHs theoretically could have
different sequences between HLA-DQB1 and HLA-DQA2 and in
the domains we skipped within the 88 kb region mentioned above,
previously published results suggest such variation would be
minimal. The MHP showed, using a set of dense SNP typings, that
a set of (HLA-DRB1*15:01, -DQB1*06:02) population haplo-
types were identical to one another centromeric to HLA-DQB1
until they split into primarily two subtypes in a region near or
within TAP2 [19]. The sudden TAP2 transition they reported was
likely both the centromeric break point of the shared sequence for
the two DR15 CEHs and the continuation of the two separate but
conserved CEH sequences we report here. Similarly, the two
B44,DR7 CEHs [16] may share essential sequence identity for the
region from HLA-B to HLA-DOB but have separate conserved
sequences on either side of that larger than 1.5 Mb region. The
two CEHs may have recombined in the early history of a common
ancestral haplotype and expanded separately.
We observed a more complex structural pattern among the
DR4,DQ8 CEHs than among the DR15 CEHs: two separate
regions of shared sequence separated by a variable region of
sequence divergence. Specifically, four DR4,DQ8 CEHs telo-
merically identical at HLA-DQB1, HLA-DQA2 and HLA-DQB2
and centromerically identical from HLA-DMB through BRD2,
each had different sequences for varying distances within the
170 kb span between the two sub-regions (Figure 4C). This
pattern may be analogous to the pattern within the core MHC
Figure 4. Shared and divergent sequences in related CEHs. A) A region of nearly identical sequence for the B8,DR3 and B18,DR3 CEHs was
previously reported [19] and is represented by the broken line rectangle, and ends just centromeric to MTC30P1, approximately 50 kb centromeric to
HLA-DQB1 [18]. B) Shared sequence for the B7,DR15 and B18,DR15 CEHs is shown in the broken line rectangle. Sequence identity for these two CEHs
ends centromerically between introns 8 and 6 of TAP2. C) Shared and divergent sequences for four DR4,DQ8 CEHs are shown in the broken line
rectangle. HLA-B*15:01 and HLA-B*40:01 are alleles of the B62 and B60 specificities, respectively.
doi:10.1371/journal.pgen.1004637.g004
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DQ8] and [HLA-B62, SC33, DR4, DQ8] (which, interestingly,
are the most divergent of the four DR4,DQ8 CEHs within the
170 kb mentioned above). These patterns of alternating blocks of
shared and divergent sequence/alleles may be a type of CEH
supergroup microvariation created by early differentiation from a
common ancestral sequence due to recombination or, perhaps
more likely, localized hypermutation followed by expansion of
separate but related CEHs.
Although our dense sequencing results raise questions specific to
the class II region, the main issue is essentially the same question
we and others have asked about CEHs generally: How can long-
range conserved sequences comprise up to half a population’s
haplotypes crossing numerous putative recombination hotspots or
regions of LD breakdown? For example, one of the strongest
reported MHC recombination hotspots is located in the TNF-
LTA region [22], yet that region is located within the core MHC,
the only human genomic region well-documented to contain
CEHs.
We conclude CEHs are recent expansions of separate ancestral
progenitors. Thus, multiple population examples of each CEH are
essentially identical by descent but have spread through the
population into pedigrees that are not now highly related. The few
mutations within a stretch of conserved sequence can be used to
calculate the age of the long-range haplotype [10,26]. However,
plausible values for the variables in such calculations are often
difficult to verify.
We also conclude LD values are not particularly useful
indicators of population haplotype architecture [3,4]. LD variation
is likely useful to demarcate localized changes in the relationships
between individual haplotypes, but LD is all too often simplistically
and incorrectly interpreted to suggest the population haplotype
architectual dominance of short blocks of conserved sequence
separated by narrow regions of relatively frequent randomized
sorting. It is likely not coincidental that the MHC is both the
region most often studied by segregation analysis in pedigrees and
the only well-documented region to contain megabase-length
CEHs.
Haplotype sequence and population haplotype architecture
accuracy requires both direct observation and the consideration of
long-range sequence fixity. Whole genome sequencing will soon
allow direct determination of full haplotype sequences if analyzed
appropriately [27]. This requires either sequencing individual
chromosomes after physical isolation [28] or sequencing moderate
to large pedigrees to phase pedigree data directly [29,30]. The
latter allows both sequence integrity crosschecking and directly
observed recombination. Samples homozygous for a particular
long-range haplotype are useful for identifying putative CEH
alleles [10,17–20,31,32], but such cell lines are rare. Direct
haplotype determination and counting [2] is the only method
capable of revealing the details of haplotype structure and
population haplotype architecture essential for disease gene
localization [4]. Computational phasing to ‘‘impute’’ haplotype
structure in unrelated subjects has been advocated for monetary or
feasibility reasons, but this does not usually provide accurate
haplotype structure [33].
Reports over 30 years show that MHC CEHs are high
population frequency (‘‘common’’) megabase-length conserved
sequences [1,3–6,8–16,23,24]. The evidence for CEH sequence
conservation (with minor microvariation) increased whenever loci
were defined at higher resolution or at intervening locations. We
update and improve the definition of the centromeric points up to
which the published reference MHC sequences essentially
represent CEH dominant sequences. The dominant class II
CEH sequences we provide (far from a complete list) should be
useful for future European Caucasian haplotype comparisons.
More complete resequencing of larger numbers of pedigree-
determined haplotypes is required to determine population
haplotype architecture both within the MHC and throughout
the genome. Furthermore, non-European CEHs [34] must be
studied in a similar manner. Finally, an appreciation of long-range
haplotype sequence conservation throughout the genome is
required to localize efficiently the genomic structural elements
responsible for complex genetic traits (including disease suscepti-
bility).
Materials and Methods
Ethics statement
All participants gave informed consent in accordance with
Institutional Review Board (IRB)-approved protocols. All work
was conducted under IRB protocols approved by the Immune
Disease Institute (or its predecessors) and/or Boston Children’s
Hospital IRBs.
Human subjects
Blood samples were provided by 180 individuals in 43 unrelated
families and by 10 unrelated subjects (the latter homozygous for
portions of the MHC), mostly from the Boston metropolitan area.
We obtained extensive demographic and personal health infor-
mation (including family histories) from all subjects. The relatively
diverse European Caucasian population in Boston and our
recruitment methods make it highly unlikely any of the pedigrees
or unrelated subjects are directly related to one another. We also
obtained B-lymphocytic cell lines of 15 individuals in four families
from the Human Biological Data Interchange (HBDI; Philadel-
phia, PA). International Histocompatibility Workshop (IHW)
homozygous cell lines (n=12), including three of the MHP
(DBB, MANN and QBL), were used for a limited number of
haplotypes. All samples had been typed at classical markers within
the MHC prior to selection, although typing was conducted at
various resolutions (from serological to high resolution DNA
typing). Pedigrees were chosen to obtain multiple examples of a
wide variety of MHC CEHs or at least the HLA-DR/DQ
fragments of CEHs putatively represented by MHP haplotypes.
HLA-DPB1 typing was not considered during subject and
haplotype selection so that the degree of fixity in the centromeric
class II region was random.
Sample extraction
DNA was extracted from EDTA-treated blood, peripheral
blood mononuclear cells or B-lymphocytic cell lines. Genomic
DNA was isolated using the QIAmp DNA mini kit (Qiagen,
Valencia, CA).
MHC Typing
Molecular MHC allele typing was performed by PCR and
sequence-specific oligonucleotide probes (in-house or Lifecodes) or
by sequence-specific primer kits (Invitrogen) at low to high
resolution. Some HLA types were identified serologically [35].
CFB (previously known as BF) and C4 allele typing was by agarose
gel electrophoresis and immunofixation with specific antisera; C2
alleles were determined by isoelectric focusing of serum in
polyacrylamide gels and a C2-sensitive hemolytic overlay [36].
MHC complement gene haplotypes or complotypes are designat-
ed by their CFB, C2, C4A, and C4B alleles, in that arbitrary order
[7]. Null or Q0 alleles are simply designated 0. Thus, FC31
indicates the complotype CFB*F, C2*C, C4A*3, C4B*1.
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[30,31]. IHW cell typing was known (http://www.ebi.ac.uk/ipd/
imgt/hla/cell_query.html) and/or verified as described above.
Alignment of MHP sequences to develop a resequencing
strategy
We analyzed eight different MHC class II and extended class II
sequences determined by the Sanger Institute [17–20] for
distinguishing SNPs and deletion/insertion polymorphisms (DIPs).
Currently available MHC sequence data for these cell lines may be
found via: http://www.ucl.ac.uk/cancer/medical-genomics/mhc
or http://www.ensembl.org/index.html or at the URL listed
under ‘‘MHC Typing.’’ MHP haplotypes represent the human
reference sequence (PGF) as well as the following alternative
sequences for the human MHC: ALT_REF_LOCI_1 (APD),
ALT_REF_LOCI_2 (COX), ALT_REF_LOCI_3 (DBB), AL-
T_REF_LOCI_4 (MANN), ALT_REF_LOCI_5 (MCF), AL-
T_REF_LOCI_6 (QBL), and ALT_REF_LOCI_7 (SSTO).
We used an amplicon-based resequencing approach [10] to
distinguish the dominant sequences of CEHs in the class II region.
CLC Combined Workbench software program (CLCBio LLC,
Cambridge, MA) was used to align these sequences for the region
from MTCO3P1 to DAXX (Figure 1). After aligning all MHP
sequence data available for the eight haplotypes, we analyzed the
entire region from MTCO3P1 to DAXX to find an optimal
distribution of amplicons that balanced the needs for relatively
even coverage and for maximizing differences between the
sequences. After preliminary resequencing and localization of
regions in which some of the MHP haplotypes appeared to cease
representing many population haplotypes or in which we had poor
sequencing results, we added or substituted amplicons. Finally, in
some cases, we skipped relatively large regions having known low
polymorphism.
DNA sequencing
We designed primers, using a version of Primer 3 software
(http://frodo.wi.mit.edu), at monomorphic (or near-monomorphic)
positions in regions near or within genes that would likely offer
maximal differentiation of the various MHP haplotypes. The
primer sequences we used and the amplicons we resequenced are
shown in Table S1. We sequenced a total of approximately 27 kb
using 56 sets of primers covering five separate regions spanning a
total distance of approximately 580 kb of genomic DNA. In some
cases where sequence phase could be determined without some
members of a particular pedigree, the DNA of those members was
not sequenced, but we often sequenced all members of a pedigree to
confirm results for a particular haplotype in multiple carriers of that
haplotype. We also sequenced portions of three MHP cell lines in
data gaps of current scaffolds, and we report and have provided that
information to GenBank.
PCR products were excised from agarose gels and purified using
the QIAEX II gel extraction kit (Qiagen) or were drawn out of
recovery wells directly (Lonza, Inc.) and sequenced by dideoxy
sequencing using Big Dye Terminator V3.0 chemistry (Genewiz,
Inc., South Plainfield, NJ and/or Davis Sequencing, Inc., Davis,
CA). All sequences were analyzed and compared using both
alignment software and direct visual inspection of chromatograms.
DIP sizes in heterozygotes were usually decipherable and
deducible in both directions based on the known sequence
surrounding the DIP. At least two individuals inspected visually
and agreed upon the sequence of each chromatogram used to
determine sequence.
Excluding private mutations, we identified 274 SNPs and DIPs
in the 342 kb region from HLA-DQA2 to HLA-DPB1 and 34
SNPs and DIPs in the 103 kb region from centromeric to RING1
to DAXX (Table S2). We defined the centromeric point where a
particular MHP sequence no longer represented a haplotype
group as the location at which the dominant sequence shared by
those haplotypes began to contain SNP and DIP alleles not in the
MHP sequence.
Haplotype assignment
The vast majority of haplotypes (n=132; 83.5%) were phased
by segregation analysis in pedigrees, showed Mendelian
inheritance patterns (except in rare cases of null alleles or
detected crossovers) and were assigned unique identifiers as
unrelated founder chromosomes. Six unrelated subjects or IHW
cell lines each known not to be consanguineous were homozy-
gous for specific haplotypes throughout the region analyzed and
provided 12 additional unrelated chromosomes (7.6%). Six
IHW cell lines either known to be consanguineous or of
unknown status provided six additional unrelated chromosomes
(3.8%). Finally, four unrelated subjects known not to be
consanguineous who were heterozygous for at least some
portion of the region studied provided the final eight unrelated
chromosomes (5.1%).
Haplotype phasing in the classical CEH region (between HLA-
C and HLA-DQB1) was established for 95% of all haplotypes or
was inferred from known CEH allele combinations. Over 96% of
SNP and DIP alleles were unambiguously phased: a) by
segregation analysis in pedigrees [1,2]; or, b) using IHW or
locally-identified MHC homozygous samples. Such cell lines were
assumed to be of consanguineous origin unless known not to be
and received only one haplotype assignment. The remaining
alleles (,4% overall and ,4% in all regions except for HLA-
DPB1, where the percentage of inferred phasing was 10.8%) were
assigned to haplotypes by inference as follows. In a family in which
all subjects were heterozygous identical at a locus or in a
heterozygous individual without relatives, one of the alleles was
arbitrarily assigned to one of the haplotypes to be consistent with
its surrounding (unambiguous) markers, defined by the unambig-
uous haplotypes in the group to which it belonged or, if the
haplotype was no longer representative, by all unambiguous
haplotypes. Phasing of the remaining pedigree haplotype(s) was/
were thus established. We report here on 158 haplotypes (and an
additional seven at HLA-DQA2) that fell into one of the eight
MHP groups.
Mapping, gene annotation and variation analysis
Physical distances between MHC genes, locations and
amplicons were found at the NCBI website (http://www.ncbi.
nlm.nih.gov/projects/genome/guide/human/index.shtml). We
used the human reference sequence NC_000006.11 from
Genome Reference Consortium assembly GRCh37.p10 and
reference sequence (rs) numbers are from dbSNP build 138. All
novel SNP (n=1)andDIP(n=7) variations (shown in Table S2)
were submitted to dbSNP (http://www.ncbi.nlm.nih.gov/snp/)
using the handle CAALPER. All novel DNA sequences for the
three MHP cell lines have GenBank accession numbers (http://
www.ncbi.nlm.nih.gov/genbank/) KF880997-KF880999 (for
QBL), KF881000-KF881006 (for MANN) and KF881007-
KF881009 (for DBB) (Figures S1–S3). To determine sequence
fixity, we assumed sequence identity within intervening regions
we did not resequence among the population haplotypes
bearing the genotypic markers and/or dominant sequence of a
CEH (except for rare private mutations and infrequent
microvariations).
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To quantify and represent crossover events leading to the
breakdown of CEH dominant sequences, we define a new metric:
normalized crossover frequency (NCF). NCF is the fraction of
remaining dominant sequences of a single CEH that begin to differ
from the dominant sequence due to apparent recombination
within a defined region, normalized over a unit (1 Mb) distance.
Our data were not distributed evenly across the region we studied,
and we therefore calculated our data over sub-regions of varying
size (Table S2). Thus, we required normalization to a unit distance
to compare the sequence breakdown by separate crossovers. We
displayed these data in a bar graph format in which the abscissa is
drawn to genomic scale. Therefore, the areas (not the heights) of
the bars representing NCFs are compared to determine the
relative contribution of regional recombinants to the breakdown of
CEH sequence conservation. NCF was calculated using the
equation:
NCF = (crossovers/total remaining haplotypes) 6 (1 Mb/
distance covered)
where:
a) ‘‘crossovers’’ are the number of haplotypes that lost the CEH
dominant sequence centromeric to the prior (telomeric) analyzed
region due to recombination events (as opposed to minor
microvariation in an otherwise identical sequence), and include
both any crossovers directly observed in the currently analyzed
region and any deduced to have occurred between the currently
and prior analyzed regions.
b) the ‘‘total remaining haplotypes’’ are the number of
remaining population haplotypes having the dominant sequence
of a given CEH throughout the region immediately telomeric to
the analyzed region. For the first region (HLA-DQA2), it was
assumed all population haplotypes of a given CEH had the
dominant sequence at the centromeric end of HLA-DQB1.
c) the ‘‘distance covered’’ is measured by subtracting the
genomic position of the most centromeric point of the prior region
(the region immediately telomeric to the currently analyzed region)
from the genomic position of the most centromeric point of the
currently analyzed region.
As an example, if 16 population haplotypes of a single CEH had
the dominant sequence through HLA-DQA2 and 3 of these
crossed over to a non-dominant sequence by the centromeric end
of the HLA-DQB2 region (in which the distance from the most
centromeric polymorphism analyzed in the HLA-DQA2 region
through the most centromeric polymorphism analyzed in the
HLA-DQB2 region is 21,096 bases), the NCF would be:
(3/16) 6(1,000,000/21,096) =8.9
and the ‘‘total remaining haplotypes’’ for the next region
(between HLA-DQB2 and HLA-DOB, covering 25,927 bases)
would be 13 (i.e., 16–3).
Supporting Information
Figure S1 Sequence data for the QBL cell line in the HLA-
DOB region. The QBL cell line was sequenced in three regions not
previously reported. Data are for the positive strand, reading from
the telomere toward the centromere, and the chromosome 6
human genome location (relative to the human reference sequence
NC_000006.11 GRCh37.p10 assembly) of the telomeric and
centromeric bases are given. Polymorphisms (SNPs and DIPs) are
shown in bold with a gray background (with DIPs double-
underlined). Sequence data were obtained from both strands
except where the sequence is single-underlined. GenBank
accession numbers are shown for each sequence.
(DOC)
Figure S2 Sequence data for the MANN cell line in the HLA-
DOB and WDR46 to DAXX regions. MANN was sequenced in
seven regions not previously reported. Data are for the positive
strand, reading from the telomere toward the centromere, and the
human chromosome 6 location (relative to the NC_000006.11
GRCh37.p10 assembly) of the telomeric and centromeric bases
are given. Polymorphisms (SNPs and DIPs) are shown in bold with
a gray background (with DIPs double-underlined). Sequence data
were obtained from both strands except where the sequence is
single-underlined. GenBank accession numbers are shown for
each sequence.
(DOC)
Figure S3 Sequence data for the DBB cell line in the BRD2
region. DBB was sequenced in three regions not previously
reported. Data are for the positive strand, reading from the
telomere toward the centromere, and the human chromosome
6 location (relative to the NC_000006.11 GRCh37.p10
assembly) of the telomeric and centromeric bases are given.
Polymorphisms (SNPs and DIPs) are shown in bold with a gray
background (with DIPs double-underlined). Sequence data
were obtained from both strands except where the sequence is
single-underlined. GenBank accession numbers are shown for
each sequence.
(DOC)
Table S1 Resequencing primers, amplification product sizes and
resequencing distance covered. Forward and reverse primer
sequences for all amplicons reported in this study are provided
along with the amplicon PCR product size and the distance
sequenced within each amplicon. The telomeric and centromeric
boundary positions of the sequenced regions are provided for each
amplicon based on the human reference sequence NC_000006.11
GRCh37.p10 assembly.
(XLS)
Table S2 Non-private polymorphisms determined from rese-
quencing. The SNPs and DIPs within the amplicons sequenced
are provided, including their local name, their reference sequence
(rs) number, their chromosomal position in the human reference
sequence (based on the NC_000006.11 GRCh37.p10 assembly)
and the amplicon name within which they were sequenced. Eleven
sub-regions for which NCF values were determined are shown on
the right.
(XLS)
Table S3 Resequencing completion for haplotypes by group and
class II region. Provides detailed information on the percentage of
completion for haplotype resequencing organized by haplotype
group, genetic region and partial and complete sequencing.
(XLS)
Table S4 MHP cell line and dominant CEH/class II fragment
haplotype sequences from HLA-DQA2 to DAXX. Not all
polymorphisms are displayed: within the boundaries of the
sequenced amplicons, cell line and CEH/dominant population
haplotype sequences contained the allele present in the human
reference sequence if not shown. Allele data for the eight cell lines
sequenced by the MHC Haplotype Project (data available from:
http://www.ucl.ac.uk/cancer/medical-genomics/mhc) are shown
along with the dominant sequence(s) we determined for related
CEHs.
(XLS)
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polymorphism sequences from telomeric to HLA-DOB to
BRD2. Within the boundaries of the sequenced amplicons,
MHP and population haplotype sequences contained alleles in
the human reference sequence if not shown. Annotated locations
have chromosome 6 positions shown in Table S2.
(XLS)
Text S1 Supplementary Results text provides more detailed
information on the regions where MHP sequences represented
European CEHs and on CEH fixity throughout the centromeric
MHC class II and extended MHC class II regions.
(DOC)
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